Alx oncology announces pricing of upsized public offering of common stock

Burlingame, calif., dec. 09, 2020 (globe newswire) -- alx oncology holdings inc. (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies to block the cd47 checkpoint pathway, today announced the pricing of an upsized underwritten public offering of 2,380,000 shares of its common stock at a price of $76.00 per share. all of the shares of common stock are being offered by alx oncology. the gross proceeds to alx oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by alx oncology, are expected to be approximately $180.9 million, excluding any exercise of the underwriters' option to purchase additional shares. the offering is expected to close on december 14, 2020, subject to the satisfaction of customary closing conditions. in addition, alx oncology has granted the underwriters a 30-day option to purchase up to an additional 357,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
ALXO Ratings Summary
ALXO Quant Ranking